• Subscribe
  • Newsfeed
  • About
  • Jobs
AI Search
Announce News

Laverock Therapeutics

To add a bio or update company history, please click update information.

News from Laverock Therapeutics

    Laverock Therapeutics raises over £20m in expanded seed round led by Calculus Capital to advance gene control therapiesLaverock Therapeutics raises over £20m in expanded seed round led by Calculus Capital to advance gene control therapies
    Laverock Therapeutics
    1 Jul 2025

    Laverock Therapeutics raises over £20m in expanded seed round led by Calculus Capital to advance gene control therapies

    Laverock Therapeutics is developing programmable gene control technologies that enable advanced therapies to respond dynamically to disease, improving precision, safety and effectiveness in cell-based treatments.

Laverock Therapeutics
  • Life Sciences
  • London, United Kingdom
  • £20m
  • laverocktx.com
  • Update Information

More venture news

  • Lightcast lands £20m in funding led by ARCH Venture Partners to advance single-cell analysis platform
    Lightcast
    15 Apr 2026

    Lightcast lands £20m in funding led by ARCH Venture Partners to advance single-cell analysis platform

    EquityLife Sciences
  • Helical raises a £7.5m seed round led by redalpine to build virtual labs for pharma research
    Helical
    14 Apr 2026

    Helical raises a £7.5m seed round led by redalpine to build virtual labs for pharma research

    SeedLife Sciences
  • Semarion secures £2.9m in funding led by Parkwalk to accelerate cell-based drug discovery
    Semarion
    31 Mar 2026

    Semarion secures £2.9m in funding led by Parkwalk to accelerate cell-based drug discovery

    EquityLife Sciences

Sign-up to our newsletter

The UK Weekly email covers every VC round from last week, firms that are hiring, and much more

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn

Announce

  • Share your story

General

  • Read the latest
  • About Soapbox

Information not up to date?

Get in touch

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn